Craig Eagle joins corporate advisory board at Provectus

KNOXVILLE, Tenn. — The VP strategic alliances and partnerships for Pfizer's oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.

Provectus Pharmaceuticals said that the company will benefit from Craig Eagle's "vast experience in drug development" as the drug maker seeks to commercialize its cancer and dermatological therapies.

Provectus is seeking approval for its novel cancer drug, PV-10, in Australia, and is slated to design a global phase-3 trial for PV-10 as a treatment for metastatic melanoma.